Bain & Company July 11, 2023
By David Harding, Dale Stafford, and Suzanne Kumar

The strategic M&A market is in limbo as both buyers and sellers navigate this weird economy.

At a Glance

  • Overall global M&A value is down 44% in the first five months of 2023.
  • Macroeconomic and interest rate uncertainty continues to complicate dealmaking and foster caution among sellers and buyers alike.
  • Valuations for strategic technology deals declined dramatically, but valuations have held steady or ticked up in most other sectors.
  • Dealmaking is likely to resume faster than many have anticipated and favor the best-prepared buyers and sellers.

We’re now 12 months into a lethargic mergers-and-acquisitions market, with deal values and volume well off postpandemic highs. Consider the mixed signals dealmakers...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Mergers & Acquisitions / JV, Survey / Study, Trends
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
A closer look at 2023's top biopharma deals and what lies ahead
Missouri hospital finalizes deal to merge with Kansas health system
Why selling to Novartis made sense for Mariana
Novartis Set to Acquire Mariana Oncology to Enhance Radioligand Therapy Pipeline

Share This Article